Genetic Risk Prediction of Atrial Fibrillation

Steven A Lubitz1, Xiaoyan Yin2, Henry J Lin2

  • 1From Cardiac Arrhythmia Service (S.A.L., P.T.E.), Cardiovascular Research Center (S.A.L., L.-C.W., S.K., P.T.E.), J. Philip Kistler Stroke Research Center, Department of Neurology (N.S.R., C.D.A., J.R.), and Center for Human Genetic Research (C.D.A., S.K., J.R.), Massachusetts General Hospital, Boston; Program in Medical and Population Genetics, Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge (S.A.L., C.D.A., L.-C.W., S.K., C.R., J.R., P.T.E.); Boston University and National Heart, Lung, and Blood Institute's Framingham Heart Study, MA (X.Y., M.G.L., K.L.L., E.J.B.); Department of Pediatrics (H.J.L., X.G., K.D.T., J.I.R.) and Institute for Translational Genomics and Population Sciences, Los Angeles Biomedical Research Institute (H.J.L., X.G., K.D.T., J.Y., J.I.R.), Harbor-UCLA Medical Center, Torrance, CA; Vanderbilt University, Nashville, TN (M.K., P.L.T., D.D.); Department of Cardiology, Clinical Sciences, Lund University, Sweden (J.G.S.); Skåne University Hospital, Lund, Sweden (J.G.S.); Departments of Cardiology (S.T., J.W.J.) and Gerontology and Geriatrics (S.T.), Leiden University Medical Center, the Netherlands; University of Groningen, University Medical Center Groningen, the Netherlands (M.R., B.G., N.V., J.E.S., P.v.d.H.); Department of Clinical Sciences, Lund University, Malmö, Sweden (P.A., G.E., O.M.); Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, Minneapolis (L.Y.C.); Robertson Center for Biostatistics (I.F.) and Institute of Cardiovascular and Medical Sciences (P.W.M., D.J.S.), University of Glasgow, UK; Department of Neurology, Rhode Island Hospital, Alpert Medical School of Brown University, Providence (K.L.F.); Department of Mathematics and Statistics, Boston University, Boston, MA (M.G.L.); Department of Biostatistics (M.G.L., K.L.L.), Department of Epidemiology (E.J.B.), Section of Cardiovascular Medicine, Department of Medicine (E.J.B.), and Preventive Medicine Section, Department of Medicine (E.J.B.), Boston University School of Public Health, MA; Cardiovascular Health Research Unit, Departments of Medicine (B.M.P., N.S., S.R.H.), Epidemiology (B.M.P., N.S., S.R.H.), and Health Services (B.M.P.), University of Washington, Seattle; Kaiser Permanente Health Research Institute, Kaiser Permanente, Seattle, WA (B.M.P., S.R.H.); Epidemiological Cardiology Research Center (EPICARE), Wake Forest School of Medicine, Winston-Salem, NC (E.Z.S.); Department of Medicine and Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, TN (D.R.); University of Illinois, Chicago (D.D.); Interuniversity Cardiology Institute of the Netherlands, Utrecht (J.W.J.); Department of Internal Medicine, Skåne University Hospital, Malmö, Sweden (O.M.); and Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA (A.A.). slubitz@mgh.harvard.edu.

Circulation
|October 30, 2016
PubMed
Abstract

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
83
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
61
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
16.4K
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
70
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
61
Human Genetics01:28

Human Genetics

Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
1.8K